Frankfurt - Delayed Quote USD

(SVQ.F)

Compare

5.58

0.00

(0.00%)

At close: February 22 at 8:19:59 AM GMT+1

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025. More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed. Heng Ren previously sent the Board a letter on March 19, and received no response. The April 8 letter urges Sinovac to pay an additional dividend of

CNW Group 8 days ago

SVA
SINOVAC Announces Decision to Declare Cash Dividend

BEIJING, April 01, 2025--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the "Board") has decided to declare a special cash dividend of US$55.00 per common share (the "Dividend"). The Board expects to fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operat

Business Wire 18 days ago

SVA
SINOVAC Announces New Board Member and Chairman of the Audit Committee

BEIJING, March 28, 2025--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the "Board") has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board.

Business Wire 22 days ago

SVA
Heng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholders

Sinovac Biotech (SVA) shareholder Heng Ren Partners, LLC funds sent an open letter to Sinovac’s shareholders outlining the significant and decisive action that Sinovac’s Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac’s Board of Directors announce a distribution of $8.9B in cash to its shareholders and cause the resumption of trading of the company’s shares. “After announcing a plan to distribute cash to shareholders,

TipRanks 29 days ago

SVQ.F
0.00%
SVA
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares.

PR Newswire 30 days ago

SVA
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

BEIJING, February 28, 2025--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the "Order") from the Privy Council following the previously announced Privy Council Judgment (the "Judgment") which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to

Business Wire last month

SVA
SINOVAC Issues Statement Regarding Privy Council Judgment

BEIJING, January 16, 2025--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company’s Rights Agreement is invalid. The ruling will take effect after e

Business Wire 3 months ago

SVA
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

BEIJING, December 16, 2024--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marketing worldwide.

Business Wire 4 months ago

SVA
SINOVAC Reports Unaudited First Half of 2024 Financial Results

BEIJING, August 16, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2024.

Business Wire 7 months ago

SVA
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

BEIJING, April 29, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual report can be accessed on the Company's investor relations website at http://www.sinovac.com/en-us/Investors. The Company also reported its unaudited financial results for the second half and audited financi

Business Wire 11 months ago

SVA

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

(SVQ.F)

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

SINOVAC Announces Decision to Declare Cash Dividend

SINOVAC Announces New Board Member and Chairman of the Audit Committee

Heng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholders

Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

SINOVAC Issues Statement Regarding Privy Council Judgment

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

SINOVAC Reports Unaudited First Half of 2024 Financial Results

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F